trending Market Intelligence /marketintelligence/en/news-insights/trending/hxR1Qy7oblp6HJKSjt03vA2 content esgSubNav
In This List

Orexigen prevails in patent litigation against Teva unit

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Orexigen prevails in patent litigation against Teva unit

Orexigen Therapeutics Inc.'s weight-loss therapy Contrave will continue to have market exclusivity after a U.S. court favored the company in its patent litigation lawsuit against Actavis Laboratories FL Inc.

The U.S. District Court for the District of Delaware upheld the validity of all the patents involved in the case, with exclusivity through 2030.

Actavis Laboratories, a unit of Teva Pharmaceutical Industries Ltd., was looking to market a generic version of the drug.